{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:47:57Z","timestamp":1780321677449,"version":"3.54.1"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenia gravis (MG) is a heterogeneous condition, characterized by autoantibodies (Abs) that target functionally important structures within neuromuscular junctions (NMJ), thus affecting nerve-to-muscle transmission. MG patients are more often now subgrouped based on the profile of serum autoantibodies, which segregate with clinical presentation, immunopathology, and their response to therapies. The serological testing plays an essential role in confirming MG diagnosis and guiding disease management, although a small percentage of MG patients remain negative for antibodies. With the advancements in new highly effective pathophysiologically-specific immunotherapeutic options, it has become increasingly important to identify the specific Abs responsible for the pathogenicity in individual MG patients. There are several new assays and protocols being developed for the improved detection of Abs in MG patients. This review focuses on the divergent immunopathological mechanisms in MG, and discusses their relevance to improved diagnostic and treatment. We propose a comprehensive \u201creflex testing,\u201d algorithm for the presence of MG autoantibodies, and foresee that in the near future, the convenience and specificity of novel assays will permit the clinicians to consider them into routine systematic testing, thus stimulating laboratories to make these tests available. Moreover, adopting treatment driven testing algorithms will be crucial to identify subgroups of patients potentially benefiting from novel immunotherapies for MG.<\/jats:p>","DOI":"10.3389\/fneur.2020.596621","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T05:09:35Z","timestamp":1607490575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Hans","family":"Frykman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Oger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission","volume":"267","author":"Vincent","year":"2000","journal-title":"Eur J Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ncl.2020.03.005","article-title":"Therapeutic and diagnostic challenges in myasthenia gravis","volume":"38","author":"Nguyen","year":"2020","journal-title":"Neurol Clin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in 'seronegative' myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","author":"Leite","year":"2008","journal-title":"Brain."},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Sci Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/cyto.b.20454","article-title":"A rapid, fluorescence-based assay for detecting antigenic modulation of the acetylcholine receptor on human cell lines","volume":"76","author":"Keefe","year":"2009","journal-title":"Cytometry B Clin Cytom."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0185976","DOI":"10.1371\/journal.pone.0185976","article-title":"Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools","volume":"12","author":"Makino","year":"2017","journal-title":"PLoS ONE."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WCO.0000000000000775","article-title":"Ocular myasthenia gravis: updates on an elusive target","volume":"33","author":"Melson","year":"2020","journal-title":"Curr Opin Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1212\/WNL.56.4.572","article-title":"In myasthenia gravis cells from atrophic thymus secrete acetylcholine receptor antibodies","volume":"56","author":"Katzberg","year":"2001","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"Romi","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00415-004-0479-z","article-title":"The significance of titin antibodies in myasthenia gravis\u2013correlation with thymoma and severity of myasthenia gravis","volume":"251","author":"Chen","year":"2004","journal-title":"J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1749-6632.1998.tb10978.x","article-title":"Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma","volume":"841","author":"Baggi","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/08916930410001708751","article-title":"Myasthenia gravis","volume":"37","author":"Vincent","year":"2004","journal-title":"Autoimmunity."},{"key":"B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Front Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pediatrneurol.2012.07.008","article-title":"Management of juvenile myasthenia gravis","volume":"48","author":"Ionita","year":"2013","journal-title":"Pediatr Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13317-019-0124-6","article-title":"Associations between HLA and autoimmune neurological diseases with autoantibodies","volume":"11","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"Auto Immun Highlights."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e36603","DOI":"10.1371\/journal.pone.0036603","article-title":"Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population","volume":"7","author":"Maniaol","year":"2012","journal-title":"PLoS ONE."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad","year":"2011","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2169\/internalmedicine.3828-19","article-title":"Anti-LRP4 antibody-associated myasthenia gravis with a rare complication of thymoma successfully treated by thymectomy","volume":"59","author":"Aoki","year":"2020","journal-title":"Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e921431","DOI":"10.12659\/AJCR.921431","article-title":"Successful transition from plasma exchange to eculizumab in acetylcholine receptor antibody- and muscle-specific kinase (MuSK) antibody-negative myasthenia gravis: a case report","volume":"21","author":"Greenwood","year":"2020","journal-title":"Am J Case Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS ONE."},{"key":"B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1017\/cjn.2017.253","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in double seronegative myasthenia gravis: a systematic review","volume":"45","author":"Bacchi","year":"2018","journal-title":"Can J Neurol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1016\/j.febslet.2013.10.001","article-title":"Mesdc2 plays a key role in cell-surface expression of Lrp4 and postsynaptic specialization in myotubes","volume":"587","author":"Hoshi","year":"2013","journal-title":"FEBS Lett."},{"key":"B45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1212\/WNL.43.8.1581","article-title":"Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin","volume":"43","author":"Gautel","year":"1993","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2013A new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.59.1.92","article-title":"The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999","volume":"59","author":"Somnier","year":"2002","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/nyas.13502","article-title":"Diagnostic utility of cortactin antibodies in myasthenia gravis","volume":"1412","author":"Illa","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cca.2015.07.030","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"449","author":"Oger","year":"2015","journal-title":"Clin Chim Acta."},{"key":"B52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc Natl Acad Sci USA."},{"key":"B53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12031-009-9271-y","article-title":"Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region","volume":"40","author":"Luo","year":"2010","journal-title":"J Mol Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1111\/j.1742-4658.2007.05935.x","article-title":"Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity","volume":"274","author":"Kalamida","year":"2007","journal-title":"FEBS J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1196\/annals.1405.021","article-title":"Autoimmunizing mechanisms in thymoma and thymus","volume":"1132","author":"Willcox","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.70.12.3334","article-title":"Studies on purified eel acetylcholine receptor and anti-acetylcholine receptor antibody","volume":"70","author":"Patrick","year":"1973","journal-title":"Proc Natl Acad Sci USA."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1212\/WNL.47.6.1552","article-title":"A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis","volume":"47","author":"Beeson","year":"1996","journal-title":"Neurology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve."},{"key":"B61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1212\/WNL.33.10.1276","article-title":"Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis","volume":"33","author":"Vincent","year":"1983","journal-title":"Neurology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1309\/AJCPYEOR6SGE8ZLU","article-title":"Detection of acetylcholine receptor modulating antibodies by flow cytometry","volume":"143","author":"Lozier","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","article-title":"Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China","volume":"301","author":"Yang","year":"2011","journal-title":"J Neurol Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e127167","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell."},{"key":"B71","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013A multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Zoltowska Katarzyna","year":"2015","journal-title":"J Neurol Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1083\/jcb.200307164","article-title":"MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction","volume":"165","author":"Cartaud","year":"2004","journal-title":"J Cell Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1","volume":"170","author":"Suzuki","year":"2005","journal-title":"J Neuroimmunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.5692\/clinicalneurol.52.1312","article-title":"New clinical entity of myasthenia gravis with autoimmune targets of heart and skeletal muscles","volume":"52","author":"Suzuki","year":"2012","journal-title":"Rinsho Shinkeigaku."},{"key":"B80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti-Kv1","volume":"21","author":"Suzuki","year":"2014","journal-title":"Eur J Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"489","DOI":"10.5692\/clinicalneurol.60.cn-001427","article-title":"A case of sporadic late-onset nemaline myopathy associated with myasthenia gravis positive for anti-titin antibody and anti-Kv1","volume":"60","author":"Kanatani","year":"2020","journal-title":"Rinsho Shinkeigaku."},{"key":"B82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jneuroim.2013.03.001","article-title":"Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis","volume":"258","author":"Suzuki","year":"2013","journal-title":"J Neuroimmunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e9192","DOI":"10.7759\/cureus.9192","article-title":"Pembrolizumab-Induced ocular myasthenic crisis","volume":"12","author":"Lorenzo","year":"2020","journal-title":"Cureus."},{"key":"B84","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"355","DOI":"10.31083\/j.jin.2020.02.1254","article-title":"Tolosa-Hunt syndrome with general myasthenia gravis involvement","volume":"19","author":"Li","year":"2020","journal-title":"J Integr Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"431","DOI":"10.5692\/clinicalneurol.cn-001270","article-title":"A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis","volume":"59","author":"Isami","year":"2019","journal-title":"Rinsho Shinkeigaku."},{"key":"B87","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.10294","article-title":"Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro","volume":"27","author":"Skeie","year":"2003","journal-title":"Muscle Nerve."},{"key":"B88","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fneur.2019.00770","article-title":"Presence of multiple autoimmune antibodies involved in concurrent myositis and myocarditis and myasthenia gravis without thymoma: a case report","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1212\/01.WNL.0000125254.99397.68","article-title":"Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis","volume":"62","author":"Takamori","year":"2004","journal-title":"Neurology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin","volume":"73","author":"Cort\u00e9s-Vicente","year":"2016","journal-title":"JAMA Neurol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e923989","DOI":"10.12659\/AJCR.923989","article-title":"Thymolipoma association with myasthenia gravis: case report","volume":"21","author":"Othman","year":"2020","journal-title":"Am J Case Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e20832","DOI":"10.1097\/MD.0000000000020832","article-title":"Effectiveness and safety of thymectomy plus prednisone compares with prednisone monotherapy for the treatment of non-thymomatous myasthenia gravis: protocol for a systematic review","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine."},{"key":"B95","doi-asserted-by":"publisher","first-page":"422","DOI":"10.21037\/jtd.2020.01.17","article-title":"Prognostic predictors of remission in ocular myasthenia after thymectomy","volume":"12","author":"Liu","year":"2020","journal-title":"J Thorac Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol."},{"key":"B98","first-page":"356","article-title":"Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report","volume":"47","author":"Nakahama","year":"2007","journal-title":"Rinsho Shinkeigaku."},{"key":"B99","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"116690","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J Neurol Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/2576117X.2019.1578164","article-title":"Longstanding and refractory anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (anti-MuSK-MG) in a child successfully treated with rituximab","volume":"69","author":"Weger","year":"2019","journal-title":"J Binocul Vis Ocul Motil."},{"key":"B103","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B104","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","article-title":"Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study","volume":"27","author":"Dos Santos","year":"2020","journal-title":"Eur J Neurol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B107","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/14712598.2020.1786530","article-title":"Eculizumab for the treatment of myasthenia gravis","volume":"20","author":"Mantegazza","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1756286420904207","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther Adv Neurol Disord."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B112","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.596621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T05:09:37Z","timestamp":1607490577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.596621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":113,"alternative-id":["10.3389\/fneur.2020.596621"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.596621","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"article-number":"596621"}}